The Latest News
IdentiTi implants are 60% porous, which enhances intra-operative and post-operative imaging.
Fourth quarter 2018 prescription growth of more than 30% from third quarter 2018
ElectroCore Announces Encouraging Research Supporting Key Areas of Clinical Development for its Non-Invasive Vagus Nerve Stimulator, gammaCore™>
Data presented at the 3rd International Brain Stimulation Conference support the use of nVNS for treatment of mild traumatic brain injury and rheumatoid arthritis
Dr. Tony Fiorino to serve as Chief Medical Officer and Brian Posner as Chief Financial Officer
Exagen and the Lupus Foundation of America Partner on New Initiative to Reduce the Time to an Accurate Lupus Diagnosis>
New tools and resources will be shared in English and Spanish through physican offices, websites and social media.
gammaCore may be medically necessary for the abortive treatment of episodic migraine and episodic cluster headaches
Addresses Significant Unmet Needs In Spine Surgery
Patient Program to Increase Awareness of Non-Drug Migraine Therapies
Findings Support the Practical Utility of Non-invasive Vagus Nerve Stimulation in Adults
Increasing Support of the Practical Utility of Non-invasive Vagus Nerve Stimulation in Adults
Collaboration to drive greater awareness about challenges facing lupus diagnosis and management
Five-year contract makes gammaCore™ available to the over 21 million patients managed within the Department of Veteran’s Affairs,
ElectroCore Receives FDA Clearance for gammaCore™ (nVNS) for Adjunctive Use for the Preventive Treatment of Cluster Headache in Adults>
First and only product
New design and development facility to support increasing patient demand.
Fnancial results for the three months and nine months ended
Results for the third quarter ended
TriSalus Life Sciences’ Pressure-Enabled Drug Delivery (PEDD) Significantly Increased Therapeutic Effect of Anti-CEA CAR-T in Pancreatic Cancer Patients with Liver Metastases>
- PEDD overpowers intratumoral high pressure, significantly increasing CAR-T into solid tumors
- Median overall survival (OS) 8.3 months and mean OS 9.8 months vs. 3 to 6 months standard of care
- Two of four stage IV patients who failed systemic chemotherapy showed metabolic complete response (CR); no visible liver metastases on PET
Developing investory management solutions to improve manufacturing profitability and streamline operations.
SupplySystem IS Leverages Advanced Technologies to Deliver a Competitive Advantage